Investing doesn’t have to be boring—on Risk & Reward, Gus and Errol dive into short-term trades, explore volatility, and keep risk in check. With equal parts energy and expertise, they show that ...

Winning your fantasy basketball league starts with finding the best fantasy basketball sleepers — undervalued NBA players with breakout potential. In this guide, we highlight mid-round value picks and ...

Conagra Brands is upgraded from sell to hold following Q1 2026 results, reflecting operational improvements and a more balanced risk/reward profile. CAG showed progress in supply chain recovery, ...

Each offseason comes with the need to make a gamble. That’s essentially what paying a free agent is much of the time. You’re paying them based on past performance in the hopes of getting similar ...

The most dangerous jobs in the United States don't always have the payoff of a sky-high salary, according to a new report from Resume Now. In fact, some of the riskiest roles don't even clear $60,000.

SoundHound has a huge opportunity with voice-first AI agents. UiPath has a big opportunity to reinvigorate growth with a spate of new partnerships. GitLab's new hybrid seat-plus-usage pricing model ...

Get The FREE Spreadsheet! What happens if you sell put options on the NASDAQ 100 ETF (QQQ) instead of just buying and holding? In this video, we backtest a systematic put-selling strategy over the ...

CorMedix surged 59% since March, driven by strong DefenCath sales and its acquisition of Melinta Therapeutics, diversifying its portfolio. DefenCath's robust Q1 and Q2 sell-in exceeded expectations, ...

Vertex isn't your run-of-the-mill biotech stock. Warren Buffett famously said that he and his investing managers "attempt to be fearful when others are greedy, and to be greedy only when others are ...